ArticleJournal of clinical orthopaedics and trauma2026
Guideline-concordant cefazolin prophylaxis in penicillin allergy labeled arthroplasty patients: Progress and persistent barriers.
Article in Journal of clinical orthopaedics and trauma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cephalosporins are recommended first-line antibiotic prophylaxis for total joint arthroplasty (TJA). However, penicillin allergy labels (PALs), which are often inaccurate, reduce cephalosporin use. In 2022, AAOS released risk-stratification guidelines based on reaction type to safely increase cephalosporin use in PAL patients, categorizing limited hypersensitivity as low-risk, anaphylaxis/angioedema as moderate-risk, and multiorgan hypersensitivity as high-risk. Cefazolin is recommended for all low-risk and some moderate-risk PAL patients, but guideline adherence remains unclear. We evaluated cefazolin administration rates and adverse drug reaction (ADR) incidence in PAL patients before and after guideline dissemination and explored potential barriers to guideline-concordance. Methods: A retrospective review was conducted on PAL patients undergoing primary TJA (total hip arthroplasty (THA), total knee arthroplasty (TKA), and total shoulder arthroplasty (TSA) at an academic center and two affiliated community hospitals between 2013 and 2024. Revisions were excluded. AAOS risk-stratification guidelines were utilized to classify patients and evaluate guideline-concordance. Date of PAL, antibiotic administration utilized for primary arthroplasty, and ADRs were collected. Results: Of 172 primary TJAs (49 THAs, 72 TKAs, 51 TSAs) from 130 patients, 92 occurred before and 80 after 2022. Cefazolin administration increased from 64% to 88% ( Conclusion: Cefazolin administration increased after guideline release, yet hesitancy persisted even in low-risk patients. All PAL patients who received cefazolin tolerated it. Documented PALs continue reducing the likelihood of receiving first-line antibiotic recommendations. PAL documentation quality and timing were identified as potential barriers to guideline-concordance. Targeted initiatives may ensure appropriate, evidence-based TJA prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.